Tech Company Financing Transactions
Phoenix Molecular Designs Funding Round
Phoenix Molecular Designs, operating out of Vancouver BC, received $2.7 million from Pallasite Ventures and private investors.
Transaction Overview
Company Name
Announced On
9/19/2018
Transaction Type
Venture Equity
Amount
$2,700,000
Round
Undisclosed
Investors
Pallasite Ventures (Lead Investor) (Christopher Bissonnette)
Proceeds Purpose
PhoenixMD intends to use the proceeds to advance its lead asset PMD-026 through IND-enabling studies and to develop a sophisticated companion diagnostic test to determine which patients have high levels of activated RSK2, the protein that PMD-026 disrupts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
887 Great Northern Way 220
Vancouver BC, V5T 4T5
Canada
Vancouver BC, V5T 4T5
Canada
Phone
Website
Email Address
Not Recorded
Overview
At Phoenix Molecular Designs, our innovative strategy for attacking cancer is based on a sophisticated lock and key mechanism where our drug will fit specifically and precisely to a protein that causes the cancer to grow unchecked, and unlock the protein to trigger cancer cell death, without affecting the normal healthy surrounding cells.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sandra Dunn
Chief Financial Officer
Michael Liggett
Chief Medical Officer
Andrew Dorr
Chief Operating Officer
Aarthi Jayanthan
Chief Scientific Officer
Gerrit Los
Chief Technical Officer
John Drie
Browse more venture capital transactions:
Prev: 9/19/2018: Illumix venture capital transaction
Next: 9/19/2018: Quantum Metric venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs